United States

AFFO (TTM)

AFFO/share (TTM)

AFFO/share Guidance

AFFO (Quarter)

AFFO/share (Quarter)

Price per share at the end of the period divided by the last reported earnings

Price/AFFO

Size (ft²)

Occupancy

The Company is a fully integrated REIT primarily focused on the ownership, acquisition, development and management of
retail properties net leased to industry leading tenants.

Agree Realty

The main earnings metric reported by the REIT

If the REIT is managed by an internal (employees) or external (separate company) team

As a long-term debt issuer, ADC is classified as investment grade

Period: 2022 Q2

Years since IPO: 15/15,
Adjusted FFO Growth: 10/15,
Adjusted FFO/share Growth: 15/20,
Dividend Growth: 20/20,
Payout Ratio: 15/15,
Debt: 15/15
            

Period: 2022 Q3

Years since IPO: 15/15,
Adjusted FFO Growth: 10/15,
Adjusted FFO/share Growth: 15/20,
Dividend Growth: 20/20,
Payout Ratio: 15/15,
Debt: 15/15
            

Period: 2022 Q4

Years since IPO: 15/15,
Adjusted FFO Growth: 13/15,
Adjusted FFO/share Growth: 18/20,
Dividend Growth: 20/20,
Payout Ratio: 15/15,
Debt: 15/15
            

Period: 2023 Q1

Years since IPO: 15/15,
Adjusted FFO Growth: 10/15,
Adjusted FFO/share Growth: 15/20,
Dividend Growth: 15/20,
Payout Ratio: 15/15,
Debt: 15/15
            

Period: 2023 Q2

Years since IPO: 15/15,
Adjusted FFO Growth: 10/15,
Adjusted FFO/share Growth: 15/20,
Dividend Growth: 15/20,
Payout Ratio: 15/15,
Debt: 15/15
            

Period: 2023 Q3

Years since IPO: 15/15,
Adjusted FFO Growth: 10/15,
Adjusted FFO/share Growth: 15/20,
Dividend Growth: 15/20,
Payout Ratio: 15/15,
Debt: 15/15
            

Period: 2023 Q4

Years since IPO: 15/15,
Adjusted FFO Growth: 13/15,
Adjusted FFO/share Growth: 18/20,
Dividend Growth: 20/20,
Payout Ratio: 15/15,
Debt: 15/15
            

Period: 2024 Q1

Years since IPO: 15/15,
Adjusted FFO Growth: 10/15,
Adjusted FFO/share Growth: 15/20,
Dividend Growth: 20/20,
Payout Ratio: 15/15,
Debt: 15/15
            

Period: 2024 Q2

Years since IPO: 15/15,
Adjusted FFO Growth: 10/15,
Adjusted FFO/share Growth: 15/20,
Dividend Growth: 20/20,
Payout Ratio: 15/15,
Debt: 15/15
            

Period: 2024 Q3

Years since IPO: 15/15,
Adjusted FFO Growth: 10/15,
Adjusted FFO/share Growth: 15/20,
Dividend Growth: 20/20,
Payout Ratio: 15/15,
Debt: 15/15
            

Period: 2024 Q4

Years since IPO: 15/15,
Adjusted FFO Growth: 15/15,
Adjusted FFO/share Growth: 20/20,
Dividend Growth: 20/20,
Payout Ratio: 15/15,
Debt: 15/15
            

Period: 2025 Q1

Years since IPO: 15/15,
Adjusted FFO Growth: 15/15,
Adjusted FFO/share Growth: 20/20,
Dividend Growth: 20/20,
Payout Ratio: 15/15,
Debt: 15/15
            

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's Adjusted FFO

Adjusted FFO Growth

Assessment of recent increases in Adjusted FFO per share, indicating profitability

Adjusted FFO/share Growth

Analysis of the recent Dividend track record

Dividend Growth

Payout level to determine if the dividend is safe

Payout Ratio

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

Interview with Joey Agree, the CEO of Agree Realty (ADC). Agree Realty is a $6B+ industry leader in the acquisition and development of properties net leased to the foremost retailers in the United States.

CEO Interview - Joey Agree of Agree Realty

MARLBOROUGH, Mass., April 24, 2025 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA), The Spatial Biology Company®, today announced the availability of a new assay designed to advance antibody-drug conjugate (ADC) development in breast cancer.

Akoya Biosciences Expands Biopharma Service Portfolio with New ADC Breast Cancer Assay and Real-world IO60 Insights at AACR 2025

ROYAL OAK, Mich. , April 23, 2025 /PRNewswire/ -- Agree Realty Corporation (NYSE: ADC) (the "Company") today announced the pricing of its public offering of 4,500,000 shares of its common stock at a public offering price of $75.70 per share in connection with the forward sale agreement described below.

Agree Realty Announces Pricing of Forward Common Stock Offering

ROYAL OAK, Mich. , April 23, 2025 /PRNewswire/ -- Agree Realty Corporation (NYSE: ADC) (the "Company") today announced that it commenced an underwritten public offering of 4,500,000 shares of its common stock in connection with the forward sale agreement described below.

Agree Realty Announces Common Stock Offering

Raises 2025 Investment Guidance to $1.3 Billion to $1.5 Billion Increases 2025 AFFO Per Share Guidance to $4.27 to $4.30 ROYAL OAK, Mich. , April 22, 2025 /PRNewswire/ -- Agree Realty Corporation (NYSE: ADC) (the "Company") today announced results for the quarter ended March 31, 2025.

Agree Realty Corporation Reports First Quarter 2025 Results

Lisata Therapeutics Inc earlier this week discussed the potential of certepetide in antibody-drug conjugate (ADC) applications through a new collaboration with Catalent. The company told investors that it entered a research license agreement with Catalent to evaluate certepetide as a payload in SMARTag dual-payload ADCs.

Lisata Therapeutics talks ADC breakthrough with Catalent – ICYMI

Vancouver, BC – TheNewswire - April 16, 2025 – GABO Mining Ltd. ( TSXV: GAB | OTCQB: MLLOF | Frankfurt: MRDN ) (the “Company” or “GABO”) is pleased to announce that a wholly owned subsidiary of the Company (Medallion Research USA, Inc.), has entered into a lease agreement dated April 14, 2025 with C Bar B Properties Corporation (the “Vendor”), pursuant to which the Company has been granted a four year lease, with exclusive option to purchase, two advanced-stage uranium exploration projects located in Utah and New Mexico, United States (collectively, the “Projects”). In connection with the transaction and to reflect its sharpened focus on uranium exploration and development, the Company also announces its intention to rebrand as GAMMA Resources Ltd. The acquisition, the name change and the associated proposed new trading symbol “GARL” are all subject to approval by the TSX Venture Exchange. “Rebranding to GAMMA Resources Ltd. reflects a deliberate and strategic realignment of our corporate identity with our mission to develop U.S.-based uranium resources that directly support the country's energy security and transition to a low-carbon future,” said Gabriel Alonso-Mendoza, the Company's President and CEO. “Additionally, with our proprietary rare earth element (REE) extraction technology currently licensed to ACDC Metals Ltd (ASX: ADC) in Australia, we are expanding our role in supplying the critical raw materials essential to both national security and global clean energy objectives.”

Gabo Mining Ltd. Announces Agreement to Acquire U.S. Uranium Projects and Proposed Name Change to Gamma Resources Ltd.

Increase Results in 2.4% Year-Over-Year Growth ROYAL OAK, Mich. , April 10, 2025 /PRNewswire/ -- Agree Realty Corporation (NYSE: ADC) (the "Company") today announced that its Board of Directors has authorized, and the Company has declared, a monthly cash dividend of $0.256 per common share, representing a 1.2% month-over-month increase.

Agree Realty Declares Increased Monthly Common Dividend

Many dividend investors seek solid passive income from quality dividend stocks.

Need Dependable Passive Income Paid Monthly? Here Are Our 5 Favorite High-Yield Stocks

ROYAL OAK, Mich. , April 2, 2025 /PRNewswire/ -- Agree Realty Corporation (NYSE: ADC) (the "Company") today announced that it will release its first quarter 2025 operating results after the market closes on Tuesday, April 22, 2025.

Agree Realty Announces First Quarter 2025 Earnings Release Date and Conference Call Information

LAUSANNE, Switzerland , April 1, 2025 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced that the Company has made grants of options to purchase an aggregate of 128,600 of the Company's common shares to two new employees on April 1, 2025 (each, a "Grant"). The Grants were offered as material inducement to the employees' employment.

ADC Therapeutics Makes Grants to New Employees Under Inducement Plan

LAUSANNE, Switzerland , April 1, 2025 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT) announced today that Ameet Mallik, Chief Executive Officer, will present a company overview at the 24th Annual Needham Virtual Healthcare Conference on Tuesday, April 8, 2025, at 8:00 a.m. ET. A live webcast of the presentation will be available via the Events & Presentations page in the Investors section of ADC Therapeutics' website, ir.adctherapeutics.com.

ADC Therapeutics to Participate in the 24th Annual Needham Virtual Healthcare Conference

Many companies have de-emphasized paying dividends over the years. That's one reason the dividend yield on the S&P 500 is only around 1.3% these days.

4 Top Dividend Stocks Yielding Around 4% to Buy Without Hesitation in April

ROYAL OAK, Mich. , March 31, 2025 /PRNewswire/ -- Agree Realty Corporation (NYSE: ADC) (the "Company") today announced the establishment of its inaugural commercial paper program.

Agree Realty Announces $625 Million Commercial Paper Program

Initial data from LOTIS-7 Phase 1b trial of ZYNLONTA® plus glofitamab demonstrated clinically meaningful benefit with 94% best ORR and 72% CR rate; data update expected in second quarter 2025 Completed enrollment in LOTIS-5 Phase 3 confirmatory trial of ZYNLONTA plus rituximab in patients with 2L+ DLBCL; data update anticipated in late 2025 once PFS events reached $250.9M in cash as of December 31, 2024, provides runway expected to fund operations into the second half of 2026 Company to host conference call today at 8:30 a.m. EDT LAUSANNE, Switzerland , March 27, 2025 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today reported financial results for the fourth quarter and full year ended December 31, 2024, and provided recent operational updates.

ADC Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Operational Update

Oral presentation to highlight preclinical investigation of Claudin-6 ADC in ovarian and NSCLC cancer models Preclinical data for PSMA and ASCT2-targeted ADCs accepted for poster presentations LAUSANNE, Switzerland , March 25, 2025 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced abstracts detailing multiple preclinical programs have been accepted for presentation at the American Association for Cancer Research (AACR) Annual Meeting 2025, taking place April 25-30, 2025, in Chicago, Illinois. "We are excited to present preclinical data on our exatecan-based Claudin-6, PSMA, and ACST2-targeting antibody-drug conjugates," said Patrick van Berkel, PhD, Chief Scientific Officer of ADC Therapeutics.

ADC Therapeutics Announces Abstracts Accepted for Presentation at the American Association for Cancer Research Annual Meeting 2025

Expression data from patient-derived xenograft (PDX) mouse models exposed to micvotabart pelidotin (MICVO) indicate gene signatures associated with efficacy, deepening understanding of MOA and potential patient response

Pyxis Oncology to Present New Preclinical Data Supporting Development of First-In-Concept ADC Targeting EDB+FN in Tumor Microenvironment at AACR 2025

SAN FRANCISCO and SUZHOU, China , March 23, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune, ophthalmology and other major diseases, announces that the first participant has been successfully dosed with IBI354 (HER2 Monoclonal Antibody-Camptothecin Derivative Conjugate, HER2 ADC) in a randomized, controlled, multicenter Phase 3 clinical trial (HeriCare-Ovarian01), for platinum-resistant ovarian cancer (PROC) with HER2 expression. HeriCare-Ovarian01 is the first Phase 3 clinical trial (NCT06834672) in China to investigate PROC with HER2 expression (IHC 1+, 2+ or 3+).

Innovent Dosed First Participant in Phase 3 Clinical Study of IBI354 (Novel HER2 ADC) for Platinum-resistant Ovarian Cancer

LAUSANNE, Switzerland , March 20, 2025 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced that it will host a conference call and live webcast on Thursday, March 27, 2025, at 8:30 a.m. EDT to report financial results for the fourth quarter and year ended December 31, 2024, and provide operational updates.

ADC Therapeutics to Host Fourth Quarter and Year-End 2024 Financial Results Conference Call on March 27, 2025

New name reflects focus on accelerating portfolio of advanced ADC therapies with speed, agility and precision Upon closing of strategic transactions, cash expected to fund operations into 2028 enabling anticipated key clinical data readouts for its ADC assets Company shares to trade on Nasdaq under the symbol "WHWK" effective March 19, 2025 Company reports financial results for the fourth quarter and full-year 2024, and will host a conference call tomorrow, March 19 at 8:30 am ET MORRISTOWN, N.J. , March 18, 2025 /PRNewswire/ -- Whitehawk Therapeutics, Inc. (Nasdaq: WHWK), formerly known as Aadi Bioscience, Inc., an oncology therapeutics company applying advanced technologies to established tumor biology to efficiently deliver improved cancer treatments, today announced it changed its name to Whitehawk Therapeutics, reflecting the Company's evolution and focus on accelerating its portfolio of antibody drug conjugates (ADCs) with speed, agility and precision.

Aadi Bioscience Relaunches as Whitehawk Therapeutics Marking Evolution into ADC Company

Dividend stocks offer a reliable way to generate monthly income without the hassles of finding a side gig, buying and managing a rental property, or any other things you learn about while doom-scrolling social media these days.

These 5 Dividend Stocks Will Pay You Like a Boss Every Month

– Sutro will rapidly advance next-generation exatecan and dual-payload ADC programs; luveltamab tazevibulin development to be deprioritized as Sutro continues to seek a partner –

Sutro Biopharma Announces Strategic Portfolio Review Resulting in the Prioritization of its Next-Generation ADC Pipeline

ROYAL OAK, Mich. , March 11, 2025 /PRNewswire/ -- Agree Realty Corporation (NYSE: ADC) (the "Company") today announced that its Board of Directors has authorized, and the Company has declared, a monthly cash dividend of $0.253 per common share.

Agree Realty Declares Monthly Common and Preferred Dividends

HONG KONG , Feb. 27, 2025 /PRNewswire/ -- Akeso, Inc. (9926.HK) announced the first patient has been enrolled in the Phase I clinical trial of AK138 D1 for the treatment of advanced malignancies in Australia. AK138D1,  a self-developed and differentiated HER3-targeting ADC (antibody-drug conjugate),  is Akeso's first ADC drug to enter clinical studies.

Akeso Announces First ADC Drug Clinical Trial, Marking a New Era for "IO 2.0 + ADC" Strategy

NEW YORK--(BUSINESS WIRE)--OS Therapies, Inc. (NYSE-A: OSTX), a clinical-stage biotechnology company advancing immunotherapies and targeted drug conjugates for cancer treatment, announced the formation of subsidiary OS Drug Conjugates (OSDC). The formation of OSDC coincides with formal strategic options initiatives to create value from the Company's leading-edge, patented silicone dioxide-based, pH sensitive tunable antibody drug conjugates (tADC) & other tunable drug conjugates (tDC) platf.

OS Therapies Forms Subsidiary OS Drug Conjugates and Initiates Review of Strategic Options for its tunable ADC & Drug Conjugates Platforms

Building on proven targeting of the F H AB domain, Sonnet's ADC platform offers flexible payload capacity and controllable drug-antibody ratios (DAR)

Sonnet BioTherapeutics Announces That Its Proprietary Antibody Drug Conjugate (ADC) Platform is Available for Drug Discovery Partnerships with Potential for Producing Multiple Pipeline Drug Candidates

MARLBOROUGH, MASS., APRIL 24, 2025 (GLOBE NEWSWIRE) -- AKOYA BIOSCIENCES, INC. (NASDAQ: AKYA), THE SPATIAL BIOLOGY COMPANY, TODAY ANNOUNCED THE AVAILABILITY OF A NEW ASSAY DESIGNED TO ADVANCE ANTIBODY-DRUG CONJUGATE (ADC) DEVELOPMENT IN BREAST CANCER.

AKOYA BIOSCIENCES EXPANDS BIOPHARMA SERVICE PORTFOLIO WITH NEW ADC BREAST CANCER ASSAY AND REAL-WORLD IO60 INSIGHTS AT AACR 2025

ROYAL OAK, MICH. , APRIL 23, 2025 /PRNEWSWIRE/ -- AGREE REALTY CORPORATION (NYSE: ADC) (THE "COMPANY") TODAY ANNOUNCED THE PRICING OF ITS PUBLIC OFFERING OF 4,500,000 SHARES OF ITS COMMON STOCK AT A PUBLIC OFFERING PRICE OF $75.70 PER SHARE IN CONNECTION WITH THE FORWARD SALE AGREEMENT DESCRIBED BELOW.

AGREE REALTY ANNOUNCES PRICING OF FORWARD COMMON STOCK OFFERING

ROYAL OAK, MICH. , APRIL 23, 2025 /PRNEWSWIRE/ --AGREE REALTY CORPORATION (NYSE: ADC) (THE "COMPANY") TODAY ANNOUNCED THAT IT COMMENCED AN UNDERWRITTEN PUBLIC OFFERING OF 4,500,000 SHARES OF ITS COMMON STOCK IN CONNECTION WITH THE FORWARD SALE AGREEMENT DESCRIBED BELOW.

AGREE REALTY ANNOUNCES COMMON STOCK OFFERING

RAISES 2025 INVESTMENT GUIDANCE TO $1.3 BILLION TO $1.5 BILLION INCREASES 2025 AFFO PER SHARE GUIDANCE TO$4.27TO$4.30 ROYAL OAK, MICH. , APRIL 22, 2025 /PRNEWSWIRE/ -- AGREE REALTY CORPORATION (NYSE:ADC) (THE "COMPANY") TODAY ANNOUNCED RESULTS FOR THE QUARTER ENDED MARCH 31, 2025.

AGREE REALTY CORPORATION REPORTS FIRST QUARTER 2025 RESULTS

INCREASE RESULTS IN 2.4% YEAR-OVER-YEAR GROWTH ROYAL OAK, MICH. , APRIL 10, 2025 /PRNEWSWIRE/ -- AGREE REALTY CORPORATION (NYSE: ADC) (THE "COMPANY") TODAY ANNOUNCED THAT ITS BOARD OF DIRECTORS HAS AUTHORIZED, AND THE COMPANY HAS DECLARED, A MONTHLY CASH DIVIDEND OF $0.256 PER COMMON SHARE, REPRESENTING A 1.2% MONTH-OVER-MONTH INCREASE.

AGREE REALTY DECLARES INCREASED MONTHLY COMMON DIVIDEND

ROYAL OAK, MICH. , APRIL 2, 2025 /PRNEWSWIRE/ -- AGREE REALTY CORPORATION (NYSE:ADC) (THE "COMPANY") TODAY ANNOUNCED THAT IT WILL RELEASE ITS FIRST QUARTER 2025 OPERATING RESULTS AFTER THE MARKET CLOSES ON TUESDAY, APRIL 22, 2025.

AGREE REALTY ANNOUNCES FIRST QUARTER 2025 EARNINGS RELEASE DATE AND CONFERENCE CALL INFORMATION

LAUSANNE, SWITZERLAND , APRIL 1, 2025 /PRNEWSWIRE/ --ADC THERAPEUTICS SA (NYSE: ADCT), A COMMERCIAL-STAGE GLOBAL LEADER AND PIONEER IN THE FIELD OF ANTIBODY DRUG CONJUGATES (ADCS), TODAY ANNOUNCED THAT THE COMPANY HAS MADE GRANTS OF OPTIONS TO PURCHASE AN AGGREGATE OF 128,600 OF THE COMPANY'S COMMON SHARES TO TWO NEW EMPLOYEES ON APRIL 1, 2025 (EACH, A "GRANT"). THE GRANTS WERE OFFERED AS MATERIAL INDUCEMENT TO THE EMPLOYEES' EMPLOYMENT.

ADC THERAPEUTICS MAKES GRANTS TO NEW EMPLOYEES UNDER INDUCEMENT PLAN

LAUSANNE, SWITZERLAND , APRIL 1, 2025 /PRNEWSWIRE/ -- ADC THERAPEUTICS SA (NYSE: ADCT) ANNOUNCED TODAY THAT AMEET MALLIK, CHIEF EXECUTIVE OFFICER, WILL PRESENT A COMPANY OVERVIEW AT THE 24TH ANNUAL NEEDHAM VIRTUAL HEALTHCARE CONFERENCE ON TUESDAY, APRIL 8, 2025, AT 8:00 A.M. ET. A LIVE WEBCAST OF THE PRESENTATION WILL BE AVAILABLE VIA THE EVENTS & PRESENTATIONS PAGE IN THE INVESTORS SECTION OF ADC THERAPEUTICS' WEBSITE, IR.ADCTHERAPEUTICS.COM.

ADC THERAPEUTICS TO PARTICIPATE IN THE 24TH ANNUAL NEEDHAM VIRTUAL HEALTHCARE CONFERENCE

ROYAL OAK, MICH. , MARCH 31, 2025 /PRNEWSWIRE/ -- AGREE REALTY CORPORATION (NYSE:ADC) (THE "COMPANY") TODAY ANNOUNCED THE ESTABLISHMENT OF ITS INAUGURAL COMMERCIAL PAPER PROGRAM.

AGREE REALTY ANNOUNCES $625 MILLION COMMERCIAL PAPER PROGRAM

INITIAL DATA FROM LOTIS-7 PHASE 1B TRIAL OF ZYNLONTA PLUS GLOFITAMAB DEMONSTRATED CLINICALLY MEANINGFUL BENEFIT WITH 94% BEST ORR AND 72% CR RATE; DATA UPDATE EXPECTED IN SECOND QUARTER 2025 COMPLETED ENROLLMENT IN LOTIS-5 PHASE 3 CONFIRMATORY TRIAL OF ZYNLONTA PLUS RITUXIMAB IN PATIENTS WITH 2L+ DLBCL; DATA UPDATE ANTICIPATED IN LATE 2025 ONCE PFS EVENTS REACHED $250.9M IN CASH AS OF DECEMBER 31, 2024, PROVIDES RUNWAY EXPECTED TO FUND OPERATIONS INTO THE SECOND HALF OF 2026 COMPANY TO HOST CONFERENCE CALL TODAY AT 8:30 A.M. EDT LAUSANNE, SWITZERLAND , MARCH 27, 2025 /PRNEWSWIRE/ -- ADC THERAPEUTICS SA (NYSE: ADCT), A COMMERCIAL-STAGE GLOBAL LEADER AND PIONEER IN THE FIELD OF ANTIBODY DRUG CONJUGATES (ADCS), TODAY REPORTED FINANCIAL RESULTS FOR THE FOURTH QUARTER AND FULL YEAR ENDED DECEMBER 31, 2024, AND PROVIDED RECENT OPERATIONAL UPDATES.

ADC THERAPEUTICS REPORTS FOURTH QUARTER AND FULL YEAR 2024 FINANCIAL RESULTS AND PROVIDES OPERATIONAL UPDATE

ORAL PRESENTATION TO HIGHLIGHT PRECLINICAL INVESTIGATION OF CLAUDIN-6 ADC IN OVARIAN AND NSCLC CANCER MODELS PRECLINICAL DATA FOR PSMA AND ASCT2-TARGETED ADCS ACCEPTED FOR POSTER PRESENTATIONS LAUSANNE, SWITZERLAND , MARCH 25, 2025 /PRNEWSWIRE/ -- ADC THERAPEUTICS SA (NYSE: ADCT), A COMMERCIAL-STAGE GLOBAL LEADER AND PIONEER IN THE FIELD OF ANTIBODY DRUG CONJUGATES (ADCS), TODAY ANNOUNCED ABSTRACTS DETAILING MULTIPLE PRECLINICAL PROGRAMS HAVE BEEN ACCEPTED FOR PRESENTATION AT THE AMERICAN ASSOCIATION FOR CANCER RESEARCH (AACR) ANNUAL MEETING 2025, TAKING PLACE APRIL 25-30, 2025, IN CHICAGO, ILLINOIS. "WE ARE EXCITED TO PRESENT PRECLINICAL DATA ON OUR EXATECAN-BASED CLAUDIN-6, PSMA, AND ACST2-TARGETING ANTIBODY-DRUG CONJUGATES," SAID PATRICK VAN BERKEL, PHD, CHIEF SCIENTIFIC OFFICER OF ADC THERAPEUTICS.

ADC THERAPEUTICS ANNOUNCES ABSTRACTS ACCEPTED FOR PRESENTATION AT THE AMERICAN ASSOCIATION FOR CANCER RESEARCH ANNUAL MEETING 2025

EXPRESSION DATA FROM PATIENT-DERIVED XENOGRAFT (PDX) MOUSE MODELS EXPOSED TO MICVOTABART PELIDOTIN (MICVO) INDICATE GENE SIGNATURES ASSOCIATED WITH EFFICACY, DEEPENING UNDERSTANDING OF MOA AND POTENTIAL PATIENT RESPONSE

PYXIS ONCOLOGY TO PRESENT NEW PRECLINICAL DATA SUPPORTING DEVELOPMENT OF FIRST-IN-CONCEPT ADC TARGETING EDB+FN IN TUMOR MICROENVIRONMENT AT AACR 2025

SAN FRANCISCO ANDSUZHOU, CHINA , MARCH 23, 2025 /PRNEWSWIRE/ -- INNOVENT BIOLOGICS, INC. ("INNOVENT") (HKEX: 01801), A WORLD-CLASS BIOPHARMACEUTICAL COMPANY THAT DEVELOPS, MANUFACTURES AND COMMERCIALIZES HIGH QUALITY MEDICINES FOR THE TREATMENT OF ONCOLOGY, CARDIOVASCULAR AND METABOLIC, AUTOIMMUNE, OPHTHALMOLOGY AND OTHER MAJOR DISEASES, ANNOUNCES THAT THE FIRST PARTICIPANT HAS BEEN SUCCESSFULLY DOSED WITH IBI354 (HER2 MONOCLONAL ANTIBODY-CAMPTOTHECIN DERIVATIVE CONJUGATE, HER2 ADC) IN A RANDOMIZED, CONTROLLED, MULTICENTER PHASE 3 CLINICAL TRIAL (HERICARE-OVARIAN01), FOR PLATINUM-RESISTANT OVARIAN CANCER (PROC) WITH HER2 EXPRESSION. HERICARE-OVARIAN01 IS THE FIRST PHASE 3 CLINICAL TRIAL (NCT06834672) IN CHINA TO INVESTIGATE PROC WITH HER2 EXPRESSION (IHC 1+, 2+ OR 3+).

INNOVENT DOSED FIRST PARTICIPANT IN PHASE 3 CLINICAL STUDY OF IBI354 (NOVEL HER2 ADC) FOR PLATINUM-RESISTANT OVARIAN CANCER

LAUSANNE, SWITZERLAND , MARCH 20, 2025 /PRNEWSWIRE/ -- ADC THERAPEUTICS SA (NYSE: ADCT), A COMMERCIAL-STAGE GLOBAL LEADER AND PIONEER IN THE FIELD OF ANTIBODY DRUG CONJUGATES (ADCS), TODAY ANNOUNCED THAT IT WILL HOST A CONFERENCE CALL AND LIVE WEBCAST ON THURSDAY, MARCH 27, 2025, AT 8:30 A.M. EDT TO REPORT FINANCIAL RESULTS FOR THE FOURTH QUARTER AND YEAR ENDED DECEMBER 31, 2024, AND PROVIDE OPERATIONAL UPDATES.

ADC THERAPEUTICS TO HOST FOURTH QUARTER AND YEAR-END 2024 FINANCIAL RESULTS CONFERENCE CALL ON MARCH 27, 2025

NEW NAME REFLECTS FOCUS ON ACCELERATING PORTFOLIO OF ADVANCED ADC THERAPIES WITH SPEED, AGILITY AND PRECISION UPON CLOSING OF STRATEGIC TRANSACTIONS, CASH EXPECTED TO FUND OPERATIONS INTO 2028 ENABLING ANTICIPATED KEY CLINICAL DATA READOUTS FOR ITS ADC ASSETS COMPANY SHARES TO TRADE ON NASDAQ UNDER THE SYMBOL "WHWK" EFFECTIVEMARCH 19, 2025 COMPANY REPORTS FINANCIAL RESULTS FOR THE FOURTH QUARTER AND FULL-YEAR 2024, AND WILL HOST A CONFERENCE CALL TOMORROW, MARCH 19 AT 8:30 AM ET MORRISTOWN, N.J. , MARCH 18, 2025 /PRNEWSWIRE/ -- WHITEHAWK THERAPEUTICS, INC. (NASDAQ: WHWK), FORMERLY KNOWN ASAADI BIOSCIENCE, INC., AN ONCOLOGY THERAPEUTICS COMPANY APPLYING ADVANCED TECHNOLOGIES TO ESTABLISHED TUMOR BIOLOGY TO EFFICIENTLY DELIVER IMPROVED CANCER TREATMENTS, TODAY ANNOUNCED IT CHANGED ITS NAME TO WHITEHAWK THERAPEUTICS, REFLECTING THE COMPANY'S EVOLUTION AND FOCUS ON ACCELERATING ITS PORTFOLIO OF ANTIBODY DRUG CONJUGATES (ADCS) WITH SPEED, AGILITY AND PRECISION.

AADI BIOSCIENCE RELAUNCHES AS WHITEHAWK THERAPEUTICS MARKING EVOLUTION INTO ADC COMPANY

 SUTRO WILL RAPIDLY ADVANCE NEXT-GENERATION EXATECAN AND DUAL-PAYLOAD ADC PROGRAMS; LUVELTAMAB TAZEVIBULIN DEVELOPMENT TO BE DEPRIORITIZED AS SUTRO CONTINUES TO SEEK A PARTNER 

SUTRO BIOPHARMA ANNOUNCES STRATEGIC PORTFOLIO REVIEW RESULTING IN THE PRIORITIZATION OF ITS NEXT-GENERATION ADC PIPELINE

ROYAL OAK, MICH. , MARCH 11, 2025 /PRNEWSWIRE/ --AGREE REALTY CORPORATION (NYSE: ADC) (THE "COMPANY") TODAY ANNOUNCED THAT ITS BOARD OF DIRECTORS HAS AUTHORIZED, AND THE COMPANY HAS DECLARED, A MONTHLY CASH DIVIDEND OF $0.253 PER COMMON SHARE.

AGREE REALTY DECLARES MONTHLY COMMON AND PREFERRED DIVIDENDS

HONG KONG , FEB. 27, 2025 /PRNEWSWIRE/ -- AKESO, INC. (9926.HK) ANNOUNCED THE FIRST PATIENT HAS BEEN ENROLLED IN THE PHASE I CLINICAL TRIAL OF AK138 D1 FOR THE TREATMENT OF ADVANCED MALIGNANCIES IN AUSTRALIA. AK138D1, A SELF-DEVELOPED AND DIFFERENTIATED HER3-TARGETING ADC (ANTIBODY-DRUG CONJUGATE), IS AKESO'S FIRST ADC DRUG TO ENTER CLINICAL STUDIES.

AKESO ANNOUNCES FIRST ADC DRUG CLINICAL TRIAL, MARKING A NEW ERA FOR "IO 2.0 + ADC" STRATEGY

NEW YORK--(BUSINESS WIRE)--OS THERAPIES, INC. (NYSE-A: OSTX), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY ADVANCING IMMUNOTHERAPIES AND TARGETED DRUG CONJUGATES FOR CANCER TREATMENT, ANNOUNCED THE FORMATION OF SUBSIDIARY OS DRUG CONJUGATES (OSDC). THE FORMATION OF OSDC COINCIDES WITH FORMAL STRATEGIC OPTIONS INITIATIVES TO CREATE VALUE FROM THE COMPANY'S LEADING-EDGE, PATENTED SILICONE DIOXIDE-BASED, PH SENSITIVE TUNABLE ANTIBODY DRUG CONJUGATES (TADC) & OTHER TUNABLE DRUG CONJUGATES (TDC) PLATF.

OS THERAPIES FORMS SUBSIDIARY OS DRUG CONJUGATES AND INITIATES REVIEW OF STRATEGIC OPTIONS FOR ITS TUNABLE ADC & DRUG CONJUGATES PLATFORMS

BUILDING ON PROVEN TARGETING OF THE F H AB DOMAIN, SONNET'S ADC PLATFORM OFFERS FLEXIBLE PAYLOAD CAPACITY AND CONTROLLABLE DRUG-ANTIBODY RATIOS (DAR)

SONNET BIOTHERAPEUTICS ANNOUNCES THAT ITS PROPRIETARY ANTIBODY DRUG CONJUGATE (ADC) PLATFORM IS AVAILABLE FOR DRUG DISCOVERY PARTNERSHIPS WITH POTENTIAL FOR PRODUCING MULTIPLE PIPELINE DRUG CANDIDATES

Agree Realty

ADC

Price

Dividends

Yield

Dividends

No items found.

Financials Overview

Financials Overview

Financial Reports

No items found.

Diversification by Property Type

Diversification by Tenant Industry

Diversification by Country

Press Releases

Related News, Articles and Videos

Historical Scores

You might also be interested in

ADC.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Dividends

Yield

Dividends

No items found.

Financials Overview

Financials Overview

Financial Reports

No items found.

Diversification by Property Type

Diversification by Tenant Industry

Diversification by Country

Press Releases

Related News, Articles and Videos

Historical Scores

You might also be interested in

ADC